Perhaps I would be better off answering that question in English, given my French language skills. The subject matter is rather technical.
We have a number of advisory groups. We also speak to the drug plan managers across the country if they have concerns or issues in the management of their drug plans. That's one source. We also talk to other experts in the field.
We have a certain expertise, and there are many others, in university research settings, for example, who have different expertise. We try very hard not to duplicate the work they might be doing. We look for gaps in research that our data can answer, which is relevant and deemed important by experts in the field.